Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 17/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | DLK1 | P80370 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774418 | 0.82 | SMYD3 (0.44) | PLATGABRA1GABRB2 | |
| SCHEMBL18403301 | 0.73 | PLAT (0.43) | PLATGABRA1GABRB2 | |
| SCHEMBL4232850 | 0.73 | PLAT (0.41) | PLATGABRA1GABRB2 | |
| SCHEMBL19938695 | 0.70 | MAP3K12 (0.51) | PLATDLK1MAP3K12GABRA1GABRB2 | |
| SCHEMBL13299192 | 0.69 | ALDH1A1 (0.53) | — | |
| SCHEMBL18403283 | 0.69 | PLAT (0.39) | PLATGABRA1GABRB2 | |
| SCHEMBL27326744 | 0.69 | SLC6A2 (0.41) | — | |
| SCHEMBL17321052 | 0.67 | KCNJ6 (0.39) | — | |
| SCHEMBL7605550 | 0.67 | PLAT (0.43) | PLATGABRA1GABRB2 | |
| SCHEMBL25946447 | 0.67 | CACNA1H (0.40) | PLATMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| EP-1907372-A1 | SUBSTITUTED CYCLOHEXYL DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2008-04-09 | — | — | EP | disclosed |
| EP-1888530-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007003965-A1 | SUBSTITUTED CYCLOHEXYL DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006120478-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | PLAT 3602/4885HDAC1 416/4885HDAC6 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.